Spots Global Cancer Trial Database for sezary syndrome
Every month we try and update this database with for sezary syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. | NCT04904146 | Mycosis Fungoid... Sezary Syndrome | Blood tests and... | 18 Years - 100 Years | Lund University Hospital | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | NCT00071071 | Cutaneous T-Cel... | HuMax-CD4 HuMax-CD4 | 18 Years - | Genmab | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | NCT03587844 | Mycosis Fungoid... Lymphomatoid Pa... Sezary Syndrome | brentuximab ved... brentuximab ved... brentuximab ved... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | NCT04256018 | Sezary Syndrome Mycosis Fungoid... | Mogamulizumab LD TSEBT | 18 Years - | Stanford University | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | NCT00157274 | Mycosis Fungoid... Sezary Syndrome | alemtuzumab | 18 Years - 75 Years | Latin American Cooperative Onco-Haematology Group - Peru | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| Ritlecitinib in CTCL | NCT05879458 | CTCL Mycosis Fungoid... Sezary Syndrome | Ritlecitinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | NCT04312841 | B-Cell Prolymph... Chronic Lymphoc... Peripheral T-Ce... Primary Cutaneo... Sezary Syndrome T-Cell Prolymph... | Letermovir | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma | NCT00748319 | Mycosis Fungici... Sezary Syndrome Dermatitis Dermatitis, Exf... | Detection of KI... | 18 Years - 95 Years | Assistance Publique - Hôpitaux de Paris | |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | NCT02341209 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Doxycycline mon... | 18 Years - | Rochester General Hospital | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| AEDV Registry of Primary Cutaneous Lymphoma | NCT03646422 | Lymphoma, T-Cel... Lymphoma, B-Cel... Lymphoma, Large... Sezary Syndrome Lymphoma, Extra... Lymphoma, B-Cel... | Registry of pat... | - | Fundación Academia Española de Dermatología | |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) | NCT00177190 | Cutaneous T-cel... Sezary Syndrome Mycosis Fungoid... | 18 Years - | University of Pittsburgh | ||
| Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma | NCT00748319 | Mycosis Fungici... Sezary Syndrome Dermatitis Dermatitis, Exf... | Detection of KI... | 18 Years - 95 Years | Assistance Publique - Hôpitaux de Paris | |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | NCT03905135 | Peripheral T-ce... Mycosis Fungoid... Sezary Syndrome Anaplastic Larg... | rhIL-15 rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | NCT02978625 | Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe... | 18 Years - | National Cancer Institute (NCI) | |
| Immunization Against Tumor Cells in Sezary Syndrome | NCT00099593 | Cutaneous T-cel... Sezary Syndrome | Autologous Dend... | 18 Years - | FDA Office of Orphan Products Development | |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | NCT04312841 | B-Cell Prolymph... Chronic Lymphoc... Peripheral T-Ce... Primary Cutaneo... Sezary Syndrome T-Cell Prolymph... | Letermovir | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) | NCT02953301 | Mycosis Fungoid... Sezary Syndrome Lymphoma, T-Cel... | resminostat Placebo | 18 Years - | 4SC AG | |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | NCT04955340 | Cutaneous T Cel... Mycosis Fungoid... Sezary Syndrome | [14C]-resminost... | 35 Years - 55 Years | 4SC AG | |
| Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma | NCT00007345 | Cutaneous T Cel... Peripheral T Ce... | Romidepsin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | NCT00178841 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Rosiglitazone a... | 18 Years - | Vanderbilt University | |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | NCT03695471 | Mycosis Fungoid... Sezary Syndrome Stage IB Mycosi... Stage II Mycosi... Stage IIA Mycos... Stage IIB Mycos... Stage III Mycos... Stage IIIA Myco... Stage IIIB Myco... Stage IV Mycosi... Stage IVA1 Myco... Stage IVA2 Myco... Stage IVB Mycos... | Pembrolizumab | 18 Years - | Mayo Clinic | |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | NCT04930653 | Folliculotropic... Primary Cutaneo... Sezary Syndrome Stage IB Mycosi... Stage II Mycosi... Stage IIA Mycos... Stage IIB Mycos... Transformed Myc... | Extracorporeal ... Mogamulizumab Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | NCT03587844 | Mycosis Fungoid... Lymphomatoid Pa... Sezary Syndrome | brentuximab ved... brentuximab ved... brentuximab ved... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | NCT00127881 | Mycosis Fungoid... Sezary Syndrome | HuMax-CD4 (zano... | 18 Years - | Emergent Product Development Seattle LLC | |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | NCT03373305 | CD30-Positive N... Folliculotropic... Recurrent Mycos... Recurrent Prima... Refractory Myco... Refractory Prim... Sezary Syndrome | Brentuximab Ved... Lenalidomide Laboratory Biom... | 18 Years - | City of Hope Medical Center | |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | NCT01396070 | Non-Hodgkin Lym... Cutaneous Lymph... Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Brentuximab ved... | 18 Years - | Stanford University | |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | NCT03905135 | Peripheral T-ce... Mycosis Fungoid... Sezary Syndrome Anaplastic Larg... | rhIL-15 rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | NCT00127881 | Mycosis Fungoid... Sezary Syndrome | HuMax-CD4 (zano... | 18 Years - | Emergent Product Development Seattle LLC | |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | NCT00127881 | Mycosis Fungoid... Sezary Syndrome | HuMax-CD4 (zano... | 18 Years - | Emergent Product Development Seattle LLC | |
| A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | NCT00611208 | T-cell Lymphoma... T-cell Leukemia Sezary Syndrome Mycosis Fungoid... Cutaneous T-cel... | A-dmDT390-bisFv... | 18 Years - | Angimmune LLC | |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | NCT01396070 | Non-Hodgkin Lym... Cutaneous Lymph... Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Brentuximab ved... | 18 Years - | Stanford University | |
| Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies | NCT05206045 | Sezary Syndrome Cutaneous T Lym... | Standard of car... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | NCT00127881 | Mycosis Fungoid... Sezary Syndrome | HuMax-CD4 (zano... | 18 Years - | Emergent Product Development Seattle LLC | |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas | NCT03373305 | CD30-Positive N... Folliculotropic... Recurrent Mycos... Recurrent Prima... Refractory Myco... Refractory Prim... Sezary Syndrome | Brentuximab Ved... Lenalidomide Laboratory Biom... | 18 Years - | City of Hope Medical Center | |
| AEDV Registry of Primary Cutaneous Lymphoma | NCT03646422 | Lymphoma, T-Cel... Lymphoma, B-Cel... Lymphoma, Large... Sezary Syndrome Lymphoma, Extra... Lymphoma, B-Cel... | Registry of pat... | - | Fundación Academia Española de Dermatología | |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) | NCT00177190 | Cutaneous T-cel... Sezary Syndrome Mycosis Fungoid... | 18 Years - | University of Pittsburgh | ||
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | NCT04676087 | Mycosis Fungoid... Primary Cutaneo... Sezary Syndrome | Extracorporeal ... Mogamulizumab Quality-of-Life... | 18 Years - | Emory University | |
| Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | NCT00896493 | Mycoses Sezary Syndrome Lymphoma, T-Cel... Bone Marrow Tra... Lymphoma, Non-H... Cutaneous T-cel... | anti-thymocyte ... cyclosporine Lymphoid radiat... | 18 Years - | Stanford University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
